| name | es-dpp4i-exclude-t1d |
| description | Determines whether DPP4i therapy is appropriate for hospitalized adults with hyperglycemia. Excludes patients with type 1 diabetes or other insulin-dependent diabetes; triggers include “Patient has T1D, is DPP4i appropriate?” and “Should a DPP4i be started in this patient?” |
Exclude type 1 diabetes and insulin-dependent diabetes from DPP4i recommendation
STEP 1 — Gather Information
Collect history of diabetes type (type 1 vs type 2), insulin dependence, C‑peptide or autoantibody results if available, current blood glucose, and prior DPP4i use.
STEP 2 — Rule In / Rule Out
Is the patient diagnosed with type 1 diabetes or other forms of insulin‑dependent diabetes?
- Yes → Exclude DPP4i; proceed to STEP 4.
- No → Continue to STEP 3.
STEP 3 — Classify or Stratify
For patients without T1D, assess suitability for DPP4i per Recommendation 7.2:
- Type 2 diabetes with recent HbA1c < 7.5 % (9.4 mmol/L), BG < 180 mg/dL (10 mmol/L), and if on insulin pre‑admission, total daily dose < 0.6 units/kg/day.
- Meets criteria → Consider DPP4i (with correction insulin or scheduled insulin).
- Does not meet criteria → Proceed to scheduled insulin therapy.
STEP 4 — Decide
- If DPP4i excluded (T1D) or patient not meeting select‑patient criteria: initiate scheduled insulin therapy (basal ± bolus ± correction) to maintain glucose 100‑180 mg/dL.
- If DPP4i appropriate: start DPP4i with correction insulin as needed; reassess glucose daily and switch to scheduled insulin if BG persistently >180 mg/dL.
Clinical Guardrails / Mimics / Pitfalls
Do not use DPP4i in known T1D or insulin‑dependent diabetes; avoid in patients with risk of severe hyperglycemia (e.g., steroid‑induced, infection) as monotherapy; monitor for BG >180 mg/dL on DPP4i and promptly switch to scheduled insulin; counsel on cost and discuss continuation after discharge; DPP4i is not a substitute for insulin in insulin‑deficient states.
Concrete Clinical Example
A 58‑year‑old admitted for community‑acquired pneumonia has known type 2 diabetes, HbA1c 7.0 %, home metformin, and admission glucose 150 mg/dL. No history of T1D. The clinician confirms non‑insulin‑dependent T2D, meets select‑patient criteria, and orders sitagliptin 100 mg daily with correction insulin sliding scale. Glucose remains 110‑160 mg/dL; DPP4i continued.
Source: Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2022, https://doi.org/10.1210/clinem/dgac278
